Metastatic Dedifferentiated Liposarcoma
Oncology·MeSH: Sarcoma
Prevalence
0.5 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| Peposertib | Accustem Sciences Inc. (ACUT) |
Frequently asked questions
How many drugs are in development for Metastatic Dedifferentiated Liposarcoma?
BioSniper tracks 1 drug in development for Metastatic Dedifferentiated Liposarcoma across 1 company.
How many clinical trials target Metastatic Dedifferentiated Liposarcoma?
There are 2 clinical trials targeting Metastatic Dedifferentiated Liposarcoma tracked by BioSniper.
What is the prevalence of Metastatic Dedifferentiated Liposarcoma?
The estimated prevalence of Metastatic Dedifferentiated Liposarcoma is approximately 0.5 per 100,000 population.
Deep-dive into Metastatic Dedifferentiated Liposarcoma
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis